Ozone Therapy in Patients with the New Coronavirus Infection COVID-19

Abstract

Aim. In our work we seek to develop new approaches for treating patients with COVID-19. The first reports about new coronavirus infection, COVID-19, came out in China in 2019. It was recognized by WHO as a pandemic crisis on March 11, 2020. Currently, there is no standard therapy protocol for COVID-19 and the drugs are used off label. Materials and methods. We have implemented ozone therapy into clinical practice as an adjuvant treatment regimen for patients with SARS-CoV-2 infection. In our study, 19 patients received ozone therapy and 18 patients were members of the control group. All patients had a positive PCR test for SARS-CoV-2 infection and were matched by the following features: sex, age, severity of symptoms, imaging data and clinical history. Patients in the study group received ozone therapy in the form of daily intravenous infusions of ozonized physiological solution (concentration: 2.2-2.4 mg/l). Conclusion. We observed a statistically significant improvement in laboratory, radiological and clinical tests of patients in the study group compared to the control group on the 14th day. Thus, we have demonstrated the benefits of using ozone therapy in patients with the new coronavirus infection COVID-19. Taking into consideration the physiological processes underlying such approach, ozone therapy should be justified for both phases: the beginning and at the peak of the disease.